Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population

Nightingale's blood biomarkers were used for prediction of severe pneumonia and COVID-19 hospitalisation in 105,146 plasma samples collected in the UK Biobank during 2007-2010.

The study found a prominent biomarker signature, involving multiple metabolic pathways, that could help to identify of those people who are susceptible for severe COVID-19 before they contract the disease.